Skip to main content
Seasonal malaria chemoprevention in Madaoua

MSF provides preventive treatment to 735,000 children in Niger, Mali and Chad

War in Gaza:: find out how we're responding
Learn more

Seasonal malaria chemoprevention treatment (SMC) has shown extremely promising results in reducing the burden of malaria in young children in the Sahel region of Africa, according to international medical organization Médecins Sans Frontières (MSF). To reach as many children as possible in remote areas it has been crucial to get the community involved. At the same time, in order to tackle the other main childhood ‘killer diseases’, MSF is screening children for malnutrition and providing vaccinations.

“The head of the community told us about the programme protecting the children under five years against the malaria disease and encouraged us to go,” explains a mother from the Karofane health area, in the Bouza district in southern Niger, where Médecins Sans Frontières / Doctors Without Borders (MSF) is carrying out a chemoprevention programme against seasonal malaria (SMC). “Last year my children suffered a lot from malaria. One was so ill he had to be admitted to hospital. But this year they’re fine.” MSF provides preventive treatment to around 735,000 children aged three months to five years in Niger, Chad and Mali between July and September.

“This year, we have treated more than double the number of children we treated last year and we have reached more areas,” says MSF epidemiologist, Alena Koscalova, MSF’s SMC advisor for Niger. In the months of July, August and September, the MSF teams provided chemopreventive treatment to some 80,000 children in Chad, over 175,000 in Mali, and more than 480,000 in Niger. SMC combines the drugs sulfadoxine-pyrimethamine and amodiaquine, and is taken in three doses, at monthly intervals, during the July-to-October rainy season when the risk of transmission is at its highest.

The combination of drugs means that patients are less likely to develop resistance. “Combination malaria therapy has been shown to considerably reduce the risks of resistance to the treatment,” says MSF health advisor, Cristian Casademont. Recent studies demonstrate that the preventive method considerably reduces the number of simple and severe cases of malaria, and leads to far fewer children being admitted to hospital with the disease

Seasonal malaria chemoprevention in Madaoua
Tounfafi, a village of 6,000 people, is one of the sites within the Madaoua district where seasonal malaria chemoprevention (SMC) has been implemented in Niger.
Juan Carlos Tomasi/MSF

Community involvement

Launching a malaria prevention campaign on this scales “is a major challenge logistically, medically and for the communities concerned,” says  Adolphe Mausid, a nurse at MSF’s project in Bouza, Niger. “The involvement of health authorities and community leaders has been fundamental. Without them, it wouldn’t have been possible. They have helped us to get closer to the communities and to gain acceptance from them.”

MSF has trained and deployed more than 4,000 community health agents to work in villages encouraging parents to take their children to the distribution points. With distribution points set up in health centres and at the houses of village leaders, as well as door-to-door distributions, the majority of children in the targeted areas have received treatment. 

The first dose of the medicine is given to the child in situ, and parents are advised on how to administer the following two doses at home. “This year, we have made great progress with the practical demonstrations,” says Koscalova. “More mothers have participated, which has enabled us to get the message across better and ensure that the treatment is administered correctly.” It’s very important they get to know the programme well and are aware of its importance,” she explains.

Seasonal malaria chemoprevention in Madaoua
Tounfafi, a village of 6,000 people, is one of the sites within the Madaoua district where seasonal malaria chemoprevention (SMC) has been implemented in Niger. 
Juan Carlos Tomasi/MSF

Malaria risk for 23 million children in the Sahel

Malaria is caused by the parasite Plasmodium, which is transmitted by the female Anopheles mosquito. Some 23 million children in the Sahel region are at risk of contracting the disease. Seasonal malaria chemoprevention, as recommended by the World Health Organization for children aged 3 to 59 months in the Sahel, “has proved to be an effective and safe strategy,” says Koscalova.

In the past three years, ministries of health in Burkina Faso, Mali, Niger, Gambia, Ghana, Guinea-Bissau, Guinea, Nigeria, Senegal, Chad and Togo have all included seasonal malaria chemoprevention in their national programmes to combat malaria.

Increasing the impact

Malaria and malnutrition are a lethal combination, so in order to increase the impact of the malaria prevention campaign, and to help reduce overall child mortality, MSF teams are also systematically screening and treating children for malnutrition, as well as vaccinating them against other diseases.

In 2014, “a new inclusion has been the updating of children’s vaccination cards,” explains Estrella Lasry, MSF tropical medicine specialist. Distribution of the Plumpy’Doz™ ready-to-use supplementary food was also included in the SMC distribution in Niger targeting children from 6 to 24 months. “In Chad and in Niger, as well as the preventive treatment against malaria, we have also vaccinated children against polio, diphtheria, tetanus, pertussis, hepatitis B and influenza in the population, with the aim of improving children’s health,” says Lasry.

At the same time, MSF teams are distributing mosquito nets treated with insecticide, which are an important means of controlling malaria, with a focus on children and pregnant women the two most vulnerable groups.

Malaria is transmitted by infected Anopheles mosquitoes. Symptoms include fever, joint pains, vomiting, nausea, convulsions and, in extreme cases, coma. The most severe form of malaria is caused in the majority of cases by the parasite Plasmodium falciparum. If untreated, it causes organ damage and ultimately death. MSF first used the strategy of seasonal malaria chemoprevention in Chad and Mali in 2012, and the following year introduced it in Niger. MSF treated a total of 1,871,200 malaria patients in its projects around the world in 2013.